
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7416456/publications.pdf Version: 2024-02-01



DETED REDE

#	Article	IF	CITATIONS
1	Resting-state EEG reveals four subphenotypes of amyotrophic lateral sclerosis. Brain, 2022, 145, 621-631.	7.6	26
2	Primary Lateral Sclerosis: Clinical, radiological and molecular features. Revue Neurologique, 2022, 178, 196-205.	1.5	15
3	Pathological neural networks and artificial neural networks in ALS: diagnostic classification based on pathognomonic neuroimaging features. Journal of Neurology, 2022, 269, 2440-2452.	3.6	28
4	Propagation patterns in motor neuron diseases: Individual and phenotype-associated disease-burden trajectories across the UMN-LMN spectrum of MNDs. Neurobiology of Aging, 2022, 109, 78-87.	3.1	17
5	Phenotypic categorisation of individual subjects with motor neuron disease based on radiological disease burden patterns: A machine-learning approach. Journal of the Neurological Sciences, 2022, 432, 120079.	0.6	25
6	Mapping cortical disease-burden at individual-level in frontotemporal dementia: implications for clinical care and pharmacological trials. Brain Imaging and Behavior, 2022, 16, 1196-1207.	2.1	7
7	Cerebellar degeneration in primary lateral sclerosis: an under-recognized facet of PLS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 542-553.	1.7	8
8	White matter microstructure alterations in frontotemporal dementia: Phenotypeâ€associated signatures and singleâ€subject interpretation. Brain and Behavior, 2022, 12, e2500.	2.2	6
9	Muscle cells of sporadic amyotrophic lateral sclerosis patients secrete neurotoxic vesicles. Journal of Cachexia, Sarcopenia and Muscle, 2022, 13, 1385-1402.	7.3	16
10	Clusters of anatomical disease-burden patterns in ALS: a data-driven approach confirms radiological subtypes. Journal of Neurology, 2022, 269, 4404-4413.	3.6	15
11	The changing landscape of neuroimaging in frontotemporal lobar degeneration: from group-level observations to single-subject data interpretation. Expert Review of Neurotherapeutics, 2022, 22, 179-207.	2.8	8
12	Cerebellar remodelling decades after spinal cord insult: neuroplasticity in poliomyelitis survivors. Journal of Integrative Neuroscience, 2022, 21, 065.	1.7	4
13	Focal thalamus pathology in frontotemporal dementia: Phenotype-associated thalamic profiles. Journal of the Neurological Sciences, 2022, 436, 120221.	0.6	12
14	The neuroradiology of upper motor neuron degeneration: PLS, HSP, ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 1-3.	1.7	2
15	Cerebellar pathology in motor neuron disease: neuroplasticity and neurodegeneration. Neural Regeneration Research, 2022, 17, 2335.	3.0	14
16	Biomarker development in amyotrophic lateral sclerosis: Challenges and viable strategies. European Journal of Neurology, 2022, 29, 1867-1868.	3.3	4
17	Neurometabolic Alterations in Motor Neuron Disease: Insights from Magnetic Resonance Spectroscopy. Journal of Integrative Neuroscience, 2022, 21, 87.	1.7	12
18	Alterations in somatosensory, visual and auditory pathways in amyotrophic lateral sclerosis: an under-recognised facet of ALS. Journal of Integrative Neuroscience, 2022, 21, 88.	1.7	9

#	Article	IF	CITATIONS
19	Motor imagery in amyotrophic lateral Sclerosis: An fMRI study of postural control. NeuroImage: Clinical, 2022, 35, 103051.	2.7	10
20	Machineâ€kearning in motor neuron diseases: Prospects and pitfalls. European Journal of Neurology, 2022, 29, 2555-2556.	3.3	7
21	The presymptomatic phase of amyotrophic lateral sclerosis: are we merely scratching the surface?. Journal of Neurology, 2021, 268, 4607-4629.	3.6	28
22	Cerebro-cerebellar white matter connectivity in bipolar disorder and associated polarity subphenotypes. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 104, 110034.	4.8	15
23	Manifold learning for amyotrophic lateral sclerosis functional loss assessment. Journal of Neurology, 2021, 268, 825-850.	3.6	23
24	Neural Correlates of Motor Imagery of Gait in Amyotrophic Lateral Sclerosis. Journal of Magnetic Resonance Imaging, 2021, 53, 223-233.	3.4	33
25	The imaging signature of C9orf72 hexanucleotide repeat expansions: implications for clinical trials and therapy development. Brain Imaging and Behavior, 2021, 15, 2693-2719.	2.1	15
26	Development of new outcome measures for adult SMA type III and IV: a multimodal longitudinal study. Journal of Neurology, 2021, 268, 1792-1802.	3.6	16
27	Degenerative and regenerative processes in amyotrophic lateral sclerosis: motor reserve, adaptation and putative compensatory changes. Neural Regeneration Research, 2021, 16, 1208.	3.0	21
28	Extra-motor cerebral changes and manifestations in primary lateral sclerosis. Brain Imaging and Behavior, 2021, 15, 2283-2296.	2.1	24
29	Extra-motor manifestations in post-polio syndrome (PPS): fatigue, cognitive symptoms and radiological features. Neurological Sciences, 2021, 42, 4569-4581.	1.9	13
30	Cognitive reserve in amyotrophic lateral sclerosis (ALS): a population-based longitudinal study. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 460-465.	1.9	22
31	Neuropsychological Assessment Should Always be Considered in Myotonic Dystrophy Type 2. Cognitive and Behavioral Neurology, 2021, 34, 1-10.	0.9	1
32	Increased cerebral integrity metrics in poliomyelitis survivors: putative adaptation to longstanding lower motor neuron degeneration. Journal of the Neurological Sciences, 2021, 424, 117361.	0.6	12
33	Infratentorial pathology in frontotemporal dementia: cerebellar grey and white matter alterations in FTD phenotypes. Journal of Neurology, 2021, 268, 4687-4697.	3.6	16
34	Genotype-associated cerebellar profiles in ALS: focal cerebellar pathology and cerebro-cerebellar connectivity alterations. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1197-1205.	1.9	36
35	Split-hand and split-limb phenomena in amyotrophic lateral sclerosis: pathophysiology, electrophysiology and clinical manifestations. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1126-1130.	1.9	25
36	The diagnostic challenge of primary lateral sclerosis: the integration of clinical, genetic and radiological cues. European Journal of Neurology, 2021, 28, 3875-3876.	3.3	1

#	Article	IF	CITATIONS
37	Cognitive network hyperactivation and motor cortex decline correlate with ALS prognosis. Neurobiology of Aging, 2021, 104, 57-70.	3.1	13
38	Frontotemporal Pathology in Motor Neuron Disease Phenotypes: Insights From Neuroimaging. Frontiers in Neurology, 2021, 12, 723450.	2.4	16
39	Evaluation and categorisation of individual patients based on white matter profiles: Single-patient diffusion data interpretation in neurodegeneration. Journal of the Neurological Sciences, 2021, 428, 117584.	0.6	10
40	Imaging data indicate cerebral reorganisation in poliomyelitis survivors: Possible compensation for longstanding lower motor neuron pathology. Data in Brief, 2021, 38, 107316.	1.0	3
41	Cortical progression patterns in individual ALS patients across multiple timepoints: a mosaic-based approach for clinical use. Journal of Neurology, 2021, 268, 1913-1926.	3.6	15
42	Imaging data reveal divergent longitudinal trajectories in PLS, ALS and poliomyelitis survivors: Group-level and single-subject traits. Data in Brief, 2021, 39, 107484.	1.0	5
43	The strength of corticomotoneuronal drive underlies ALS split phenotypes and reflects early upper motor neuron dysfunction. Brain and Behavior, 2021, 11, e2403.	2.2	4
44	Adaptive functional reorganization in amyotrophic lateral sclerosis: coexisting degenerative and compensatory changes. European Journal of Neurology, 2020, 27, 121-128.	3.3	65
45	Neuroimaging data indicate divergent mesial temporal lobe profiles in amyotrophic lateral sclerosis, Alzheimer's disease and healthy aging. Data in Brief, 2020, 28, 104991.	1.0	6
46	SMA: REGISTRIES, BIOMARKERS & OUTCOME MEASURES. Neuromuscular Disorders, 2020, 30, S99-S100.	0.6	0
47	Development and validation of a 1-year survival prognosis estimation model for Amyotrophic Lateral Sclerosis using manifold learning algorithm UMAP. Scientific Reports, 2020, 10, 13378.	3.3	38
48	Amygdala pathology in amyotrophic lateral sclerosis and primary lateral sclerosis. Journal of the Neurological Sciences, 2020, 417, 117039.	0.6	33
49	Evolving diagnostic criteria in primary lateral sclerosis: The clinical and radiological basis of "probable PLS― Journal of the Neurological Sciences, 2020, 417, 117052.	0.6	28
50	Consideration of <i>C9orf72</i> -associated ALS-FTD as a neurodevelÂopmental disorder: insights from neuroimaging. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1138-1138.	1.9	15
51	MRI data confirm the selective involvement of thalamic and amygdalar nuclei in amyotrophic lateral sclerosis. Data in Brief, 2020, 32, 106246.	1.0	15
52	Imaging and clinical data indicate considerable disease burden in â€~probable' PLS: Patients with UMN symptoms for 2–4 years. Data in Brief, 2020, 32, 106247.	1.0	10
53	"Switchboard―malfunction in motor neuron diseases: Selective pathology of thalamic nuclei in amyotrophic lateral sclerosis and primary lateral sclerosis. NeuroImage: Clinical, 2020, 27, 102300.	2.7	45
54	Commissural fiber degeneration in motor neuron diseases. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 321-323.	1.7	0

#	Article	IF	CITATIONS
55	Connectomeâ€Based Propagation Model in Amyotrophic Lateral Sclerosis. Annals of Neurology, 2020, 87, 725-738.	5.3	51
56	Progressive brainstem pathology in motor neuron diseases: Imaging data from amyotrophic lateral sclerosis and primary lateral sclerosis. Data in Brief, 2020, 29, 105229.	1.0	16
57	Thalamic, hippocampal and basal ganglia pathology in primary lateral sclerosis and amyotrophic lateral sclerosis: Evidence from quantitative imaging data. Data in Brief, 2020, 29, 105115.	1.0	17
58	The French national protocol for Kennedy's disease (SBMA): consensus diagnostic and management recommendations. Orphanet Journal of Rare Diseases, 2020, 15, 90.	2.7	31
59	Neuroimaging in primary lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 18-27.	1.7	21
60	Preface: promoting research in PLS: current knowledge and future challenges. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 1-2.	1.7	6
61	Post-polio Syndrome: More Than Just a Lower Motor Neuron Disease. Frontiers in Neurology, 2019, 10, 773.	2.4	59
62	The clinical and radiological profile of primary lateral sclerosis: a population-based study. Journal of Neurology, 2019, 266, 2718-2733.	3.6	58
63	Patterned functional network disruption in amyotrophic lateral sclerosis. Human Brain Mapping, 2019, 40, 4827-4842.	3.6	65
64	Hippocampal pathology in amyotrophic lateral sclerosis: selective vulnerability of subfields and their associated projections. Neurobiology of Aging, 2019, 84, 178-188.	3.1	59
65	Brainstem pathology in amyotrophic lateral sclerosis and primary lateral sclerosis: A longitudinal neuroimaging study. NeuroImage: Clinical, 2019, 24, 102054.	2.7	59
66	Absence of hyperexcitability of spinal motoneurons in patients with amyotrophic lateral sclerosis. Journal of Physiology, 2019, 597, 5445-5467.	2.9	22
67	The histological correlates of imaging metrics: postmortem validation of in vivo findings. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 457-460.	1.7	6
68	Presymptomatic spinal cord pathology in <i>c9orf72</i> mutation carriers: A longitudinal neuroimaging study. Annals of Neurology, 2019, 86, 158-167.	5.3	71
69	Spinal Cord Imaging in Amyotrophic Lateral Sclerosis: Historical Concepts—Novel Techniques. Frontiers in Neurology, 2019, 10, 350.	2.4	55
70	Clinical Measures of Bulbar Dysfunction in ALS. Frontiers in Neurology, 2019, 10, 106.	2.4	95
71	Machine Learning in Amyotrophic Lateral Sclerosis: Achievements, Pitfalls, and Future Directions. Frontiers in Neuroscience, 2019, 13, 135.	2.8	102
72	Pathological Crying and Laughing in Motor Neuron Disease: Pathobiology, Screening, Intervention. Frontiers in Neurology, 2019, 10, 260.	2.4	40

#	Article	IF	CITATIONS
73	Tracking a Fast-Moving Disease: Longitudinal Markers, Monitoring, and Clinical Trial Endpoints in ALS. Frontiers in Neurology, 2019, 10, 229.	2.4	67
74	Neurophysiological markers of network dysfunction in neurodegenerative diseases. Neurolmage: Clinical, 2019, 22, 101706.	2.7	27
75	Dysfunction of attention switching networks in amyotrophic lateral sclerosis. NeuroImage: Clinical, 2019, 22, 101707.	2.7	18
76	A ferroptosis–based panel of prognostic biomarkers for Amyotrophic Lateral Sclerosis. Scientific Reports, 2019, 9, 2918.	3.3	91
77	Widespread subcortical grey matter degeneration in primary lateral sclerosis: a multimodal imaging study with genetic profiling. NeuroImage: Clinical, 2019, 24, 102089.	2.7	60
78	Editorial: Biomarkers and Clinical Indicators in Motor Neuron Disease. Frontiers in Neurology, 2019, 10, 1318.	2.4	2
79	Furosemide Unmasks Inhibitory Dysfunction after Spinal Cord Injury in Humans: Implications for Spasticity. Journal of Neurotrauma, 2019, 36, 1469-1477.	3.4	8
80	Primary lateral sclerosis: a distinct entity or part of the ALS spectrum?. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 133-145.	1.7	69
81	The spinal and cerebral profile of adult spinal-muscular atrophy: A multimodal imaging study. NeuroImage: Clinical, 2019, 21, 101618.	2.7	54
82	Characteristic Increases in EEG Connectivity Correlate With Changes of Structural MRI in Amyotrophic Lateral Sclerosis. Cerebral Cortex, 2019, 29, 27-41.	2.9	76
83	Connectivity-based characterisation of subcortical grey matter pathology in frontotemporal dementia and ALS: a multimodal neuroimaging study. Brain Imaging and Behavior, 2018, 12, 1696-1707.	2.1	89
84	Multimodal spinal cord MRI offers accurate diagnostic classification in ALS. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1220-1221.	1.9	62
85	Longitudinal structural changes in ALS: a three time-point imaging study of white and gray matter degeneration. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 232-241.	1.7	82
86	Revisiting the pathoanatomy of pseudobulbar affect: mechanisms beyond corticobulbar dysfunction. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 4-6.	1.7	26
87	Clinical and Radiological Markers of Extra-Motor Deficits in Amyotrophic Lateral Sclerosis. Frontiers in Neurology, 2018, 9, 1005.	2.4	73
88	Biomarkers of Spinal and Bulbar Muscle Atrophy (SBMA): A Comprehensive Review. Frontiers in Neurology, 2018, 9, 844.	2.4	29
89	The motor unit number index (MUNIX) profile of patients with adult spinal muscular atrophy. Clinical Neurophysiology, 2018, 129, 2333-2340.	1.5	33
90	Occulomotor Neural Integrator Dysfunction in Multiple Sclerosis: Insights From Neuroimaging. Frontiers in Neurology, 2018, 9, 691.	2.4	4

#	Article	IF	CITATIONS
91	The changing landscape of motor neuron disease imaging: the transition from descriptive studies to precision clinical tools. Current Opinion in Neurology, 2018, 31, 431-438.	3.6	54
92	Extrapyramidal deficits in ALS: a combined biomechanical and neuroimaging study. Journal of Neurology, 2018, 265, 2125-2136.	3.6	45
93	A pharmaco-metabolomics approach in a clinical trial of ALS: Identification of predictive markers of progression. PLoS ONE, 2018, 13, e0198116.	2.5	64
94	The Clinical and Radiological Spectrum of Hippocampal Pathology in Amyotrophic Lateral Sclerosis. Frontiers in Neurology, 2018, 9, 523.	2.4	27
95	Imaging Cerebral Activity in Amyotrophic Lateral Sclerosis. Frontiers in Neurology, 2018, 9, 1148.	2.4	55
96	Visual encoding, consolidation, and retrieval in amyotrophic lateral sclerosis: executive function as a mediator, and predictor of performance. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 193-201.	1.7	17
97	From qualitative radiological cues to machine learning: MRI-based diagnosis in neurodegeneration. Future Neurology, 2017, 12, 5-8.	0.5	9
98	Clinical Reasoning: Reversible gait ataxia. Neurology, 2017, 88, e145-e149.	1.1	1
99	Survival prediction in Amyotrophic lateral sclerosis based on MRI measures and clinical characteristics. BMC Neurology, 2017, 17, 73.	1.8	71
100	A Crossâ€sectional populationâ€based investigation into behavioral change in amyotrophic lateral sclerosis: subphenotypes, staging, cognitive predictors, and survival. Annals of Clinical and Translational Neurology, 2017, 4, 305-317.	3.7	63
101	Identifying behavioural changes in ALS: Validation of the Beaumont Behavioural Inventory (BBI). Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 68-73.	1.7	64
102	Neuroimaging patterns along the ALS-FTD spectrum: a multiparametric imaging study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 611-623.	1.7	63
103	An exploration of the spectrum of peri -ictal MRI change; a comprehensive literature review. Seizure: the Journal of the British Epilepsy Association, 2017, 50, 19-32.	2.0	54
104	Virtual brain biopsies in amyotrophic lateral sclerosis: Diagnostic classification based on in vivo pathological patterns. NeuroImage: Clinical, 2017, 15, 653-658.	2.7	66
105	Deciphering neurodegeneration. Neurology, 2017, 89, 1758-1759.	1.1	17
106	The spectrum of peri-ictal MRI changes; four illustrative cases. Seizure: the Journal of the British Epilepsy Association, 2017, 50, 189-193.	2.0	11
107	Carbapenems and valproate: A consumptive relationship. Epilepsia Open, 2017, 2, 107-111.	2.4	11
108	Mismatch Negativity as an Indicator of Cognitive Sub-Domain Dysfunction in Amyotrophic Lateral Sclerosis. Frontiers in Neurology, 2017, 8, 395.	2.4	24

#	Article	IF	CITATIONS
109	From pneumomyelography to cord tractography: historical perspectives on spinal imaging. Future Neurology, 2017, 12, 121-124.	0.5	2
110	'Khatatonia' - cathinone-induced hypertensive encephalopathy. Netherlands Journal of Medicine, 2017, 75, 448-450.	0.5	3
111	Measurement of Social Cognition in Amyotrophic Lateral Sclerosis: A Population Based Study. PLoS ONE, 2016, 11, e0160850.	2.5	63
112	The segmental diffusivity profile of amyotrophic lateral sclerosis associated white matter degeneration. European Journal of Neurology, 2016, 23, 1361-1371.	3.3	63
113	Palliative Care and End of Life Care. , 2016, , 305-319.		2
114	The selective anatomical vulnerability of ALS: â€~disease-defining' and â€~disease-defying' brain regions. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 561-570.	1.7	57
115	Discordant performance on the â€~Reading the Mind in the Eyes' Test, based on disease onset in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 467-472.	1.7	46
116	A large-scale multicentre cerebral diffusion tensor imaging study in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 570-579.	1.9	138
117	Development of an Automated MRI-Based Diagnostic Protocol for Amyotrophic Lateral Sclerosis Using Disease-Specific Pathognomonic Features: A Quantitative Disease-State Classification Study. PLoS ONE, 2016, 11, e0167331.	2.5	65
118	A second-generation Irish genome-wide association study for amyotrophic lateral sclerosis. Neurobiology of Aging, 2015, 36, 1221.e7-1221.e13.	3.1	10
119	Presymptomatic and longitudinal neuroimaging in neurodegeneration—from snapshots to motion picture: a systematic review. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 1089-1096.	1.9	78
120	Predicting prognosis in amyotrophic lateral sclerosis: a simple algorithm. Journal of Neurology, 2015, 262, 1447-1454.	3.6	84
121	Basal ganglia pathology in ALS is associated with neuropsychological deficits. Neurology, 2015, 85, 1301-1309.	1.1	96
122	Patterns of cerebral and cerebellar white matter degeneration in ALS: FigureÂ1. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 468-470.	1.9	58
123	Fecundity in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2014, 15, 204-206.	1.7	5
124	Sexual dimorphism in ALS: Exploring gender-specific neuroimaging signatures. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2014, 15, 235-243.	1.7	53
125	Revisiting the spectrum of lower motor neuron diseases with snake eyes appearance on magnetic resonance imaging. European Journal of Neurology, 2014, 21, 1233-1241.	3.3	52
126	"Sand-watch―spinal cord: a case of inferior cervical spinal cord atrophy. Journal of Neurology, 2014, 261, 235-237.	3.6	12

#	Article	IF	CITATIONS
127	Lessons of ALS imaging: Pitfalls and future directions — A critical review. NeuroImage: Clinical, 2014, 4, 436-443.	2.7	98
128	Subcortical gray matter structures: a future biomarker for amyotrophic lateral sclerosis?. Future Neurology, 2014, 9, 109-111.	0.5	0
129	Grey matter correlates of clinical variables in amyotrophic lateral sclerosis (ALS): a neuroimaging study of ALS motor phenotype heterogeneity and cortical focality. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 766-773.	1.9	121
130	Multiparametric MRI study of ALS stratified for the <i>C9orf72</i> genotype. Neurology, 2013, 81, 361-369.	1.1	150
131	Basal ganglia involvement in amyotrophic lateral sclerosis. Neurology, 2013, 81, 2107-2115.	1.1	147
132	Cognitive changes predict functional decline in ALS. Neurology, 2013, 80, 1590-1597.	1.1	237
133	Aggregation of neurologic and neuropsychiatric disease in amyotrophic lateral sclerosis kindreds: A populationâ€based case–control cohort study of familial and sporadic amyotrophic lateral sclerosis. Annals of Neurology, 2013, 74, 699-708.	5.3	116
134	Spinal cord markers in ALS: Diagnostic and biomarker considerations. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 407-415.	2.1	50
135	Absence of consensus in diagnostic criteria for familial neurodegenerative diseases. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 365-367.	1.9	65
136	The syndrome of cognitive impairment in amyotrophic lateral sclerosis: a population-based study. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 102-108.	1.9	557
137	Neuroimaging in amyotrophic lateral sclerosis. Biomarkers in Medicine, 2012, 6, 319-337.	1.4	133
138	Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: a population-based cohort study. Lancet Neurology, The, 2012, 11, 232-240.	10.2	493
139	Palliative care in amyotrophic lateral sclerosis: a review of current international guidelines and initiatives. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 413-418.	1.9	95
140	On the development of markers for pathological TDP-43 in amyotrophic lateral sclerosis with and without dementia. Progress in Neurobiology, 2011, 95, 649-662.	5.7	47
141	Executive dysfunction is a negative prognostic indicator in patients with ALS without dementia. Neurology, 2011, 76, 1263-1269.	1.1	324
142	Waterskier's Hirayama syndrome. Journal of Neurology, 2011, 258, 2078-2079.	3.6	10
143	Rate of familial amyotrophic lateral sclerosis: a systematic review and meta-analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 623-627.	1.9	283
144	Proposed criteria for familial amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2011, 12, 157-159.	2.1	120